• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Teva to buy Allergan's generic business


<







we need growth beyond volume. Once we get on that treadmill Brent needs to get revenues somewhere. They just bought Naurex on the cheap so bravo for that. But who ever believes anything management says!
 
















So all that change over the last year, and we are basically back to being Allergan. WTF? Someone put the for sale sign on our yard please.

You/we aren't Allergan, it's just a name now, a name on a shell of a "company." Allergan, Forest, Actavis are all in the history books now. This is the M&A Wall Street machine, not a real company anymore.
 




So much for the US stopping inversion ... with the sell of generics Allergan has effectively inverted to Irish domain, and upgraded to a management that will leverage a balance sheet.